Document is current
Any future updates will be listed below
-
Authors
Lu, Xiaocui
Wang, Xiuyun
Yang, Zheng
Wang, Xusheng
Wang, Lin
Xu, Chunhui https://orcid.org/0000-0002-3836-3179
Lo, I-Chung
Geng, Chenlu
Wang, Lin https://orcid.org/0000-0003-2482-7638
Pu, Yisheng
Zhang, Keyu
Zhu, Ziqiang
Ye, Lanxin
Huang, Jiayuan
Wei, Xiaofan
Bai, Fang https://orcid.org/0000-0003-1468-5568
Zhu, Yanan https://orcid.org/0000-0003-1025-7929
Qian, Xiaobing
Dou, Hao https://orcid.org/0009-0000-2866-9011
Su, Hexiu https://orcid.org/0009-0007-5682-8738
Cang, Yong https://orcid.org/0000-0002-1148-7008
- License Information
-
More Information
Article History
Received: 4 August 2025
Accepted: 30 April 2026
First Online: 10 June 2026
Competing interests
: Z.Y., L.W. (Degron Therapeutics), C.X., I-C.L., C.G., X.Q., H.D. and H.S. are current employees and shareholders of Degron Therapeutics. Y.C. is a shareholder and consultant of Degron Therapeutics, and receives research funding from Degron Therapeutics. Z.Y., H.S., C.G. and H.D. have a patent related to this work: WO2024114639A, titled ‘Compounds for modulating HuR ( ELAVL1 )’; these authors declare no other competing interests. The other authors declare no competing interests.
